BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2311176)

  • 1. Phase II study of teniposide in advanced breast cancer.
    Boas J; Rasmussen D; Hansen OP; Engelholm SA; Dombernowsky P
    Cancer Chemother Pharmacol; 1990; 25(6):463-4. PubMed ID: 2311176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II evaluation of teniposide (VM-26) in metastatic breast carcinoma. A Southeastern Cancer Study Group trial.
    Cox EB; Vogel CL; Carpenter JT; Raney M
    Invest New Drugs; 1988 Apr; 6(1):37-9. PubMed ID: 3410666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of VM-26 in adult malignancies.
    Spremulli E; Schulz JJ; Speckhart VJ; Wampler GL
    Cancer Treat Rep; 1980 Jan; 64(1):147-9. PubMed ID: 7379049
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase II study of teniposide in adenocarcinoma of the lung.
    Sørensen JB; Bach F; Dombernowsky P; Hansen HH
    Cancer Chemother Pharmacol; 1991; 27(6):487-9. PubMed ID: 2013120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Teniposide in recurrent or advanced cervical carcinoma: a phase II trial in patients not previously treated with cytotoxic therapy.
    Pfeiffer P; Cold S; Bertelsen K; Panduro J; Sandberg E; Rose C
    Gynecol Oncol; 1990 May; 37(2):230-3. PubMed ID: 2344968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II trial of teniposide (VM 26) in advanced non-Hodgkin's lymphoma, with emphasis on the treatment of elderly patients.
    Tirelli U; Carbone A; Crivellari D; Volpe R; Franchin G; Veronesi A; Galligioni E; Trovò M; Tumolo S; Grigoletto E
    Cancer; 1984 Aug; 54(3):393-6. PubMed ID: 6375853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VM-26 in colorectal carcinoma: a Southwest Oncology Group study.
    Oishi N; Fleming TR; Laufman L; Ungerleider JS; Natale RB; Einstein AB; Von Hoff DD; Macdonald JS
    Invest New Drugs; 1990 Feb; 8(1):93-5. PubMed ID: 2188930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Teniposide in the treatment of non-small cell lung carcinoma.
    Giaccone G; Donadio M; Ferrati P; Bonardi G; Ciuffreda L; Bagatella M; Calciati A
    Cancer Treat Rep; 1987 Jan; 71(1):83-5. PubMed ID: 3024829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teniposide in advanced breast cancer. A phase II trial in patients with no prior chemotherapy.
    Nielsen D; Boas J; Engelholm SA; Hansen OP; Dombernowsky P
    Ann Oncol; 1992 May; 3(5):377-8. PubMed ID: 1616891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II evaluation of VM-26 in patients with metastatic transitional cell carcinoma of the urinary tract: an Eastern Cooperative Oncology Group study.
    Qazi R; Elson P; Khandekar JD
    Cancer Treat Rep; 1982 Feb; 66(2):405-6. PubMed ID: 7055823
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase I study of oral teniposide (VM-26).
    Smit EF; Ousterhuis BE; Berendsen HH; Sleijfer DT; Postmus PE
    Semin Oncol; 1992 Apr; 19(2 Suppl 6):35-9. PubMed ID: 1329226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of teniposide (VM-26) in multiple myeloma.
    Tirelli U; Carbone A; Zagonei V; Brema F; Veronesi A; Grigoletto E; Volpe R
    Am J Clin Oncol; 1985 Aug; 8(4):329-31. PubMed ID: 3909805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose teniposide for refractory malignancies: a phase I study.
    de Vries EG; Mulder NH; Postmus PE; Vriesendorp R; Willemse PH; Sleijfer DT
    Cancer Treat Rep; 1986 May; 70(5):595-8. PubMed ID: 3708608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of VM 26 in extensively pretreated breast cancer.
    Tirelli U; Franchin G; Crivellari D; Veronesi A; Galligioni E; Trovó MG; Talamini R; Tumolo S; Grigoletto E
    Am J Clin Oncol; 1984 Oct; 7(5):451-2. PubMed ID: 6507365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Teniposide is not effective in chronic lymphocytic leukemia.
    Zagonel V; Tirelli U; Veronesi A; Galligioni E; Tumolo S; Roncadin M; Carbone A; Grigoletto E
    Blut; 1986 Jan; 52(1):59-61. PubMed ID: 3632912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of daily oral teniposide for 20 days.
    Smit EF; Splinter TA; Kok TC
    Semin Oncol; 1992 Apr; 19(2 Suppl 6):40-2. PubMed ID: 1411637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teniposide (VM-26) in patients with advanced refractory ovarian cancer: a phase II study of the Netherlands Joint Study Group for Ovarian Cancer.
    van der Burg ME; ten Bokkel Huinink WW; Vriesendorp R; van Oosterom AT; Neijt JP; Vermorken JB; van Putten WL; Kooiman A
    Eur J Cancer Clin Oncol; 1987 Jul; 23(7):997-8. PubMed ID: 3666002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Teniposide (VM26): an effective treatment for brain metastases of small cell carcinoma of the lung.
    Giaccone G; Donadio M; Bonardi GM; Testore F; Calciati A
    Eur J Cancer Clin Oncol; 1988 Apr; 24(4):629-31. PubMed ID: 2838291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teniposide (VM-26) in patients with non-squamous-cell carcinoma of the cervix. A phase II trial of the Gynecologic Oncology Group.
    Muss HB; Bundy BN; Given FT; Stehman FB
    Am J Clin Oncol; 1990 Apr; 13(2):117-8. PubMed ID: 2316480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teniposide in refractory ovarian cancer: a phase II study.
    Sessa C; D'Incalci M; Landoni F; Colombo N; Mangioni C
    Cancer Treat Rep; 1984 May; 68(5):815-6. PubMed ID: 6722838
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.